Bacterial pneumonia cost-effectiveness of therapy: Difference between revisions
Created page with "__NOTOC__ {{Bacterial pneumonia}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{..." |
m corrected my editor hyperlink |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Bacterial pneumonia}} | {{Bacterial pneumonia}} | ||
'''Editor-In-Chief:''' [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [Mailto:charlesmichaelgibson@gmail.com| <nowiki>[1]</nowiki>]; '''Associate Editor(s)-in-Chief:''' [[User:AroojNaz|Arooj Naz, M.B.B.S]] | |||
==Overview== | |||
The use of [[Antibiotic|antibiotics]] and [[corticosteroids]] had proven to be a cost-effective strategy in treating [[community-acquired pneumonia]]. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective.<ref name="pmid30448195">{{cite journal| author=Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E| title=The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia. | journal=Chest | year= 2019 | volume= 155 | issue= 4 | pages= 787-794 | pmid=30448195 | doi=10.1016/j.chest.2018.11.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30448195 }} </ref> The cost effectiveness of ceftolozane/[[tazobactam]] versus [[meropenem]] was also analyzed and resulted in significant savings in early treatment.<ref name="pmid33837518">{{cite journal| author=Naik J, Puzniak L, Critchlow S, Elsea D, Dillon RJ, Yang J| title=Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. | journal=Infect Dis Ther | year= 2021 | volume= 10 | issue= 2 | pages= 939-954 | pmid=33837518 | doi=10.1007/s40121-021-00436-4 | pmc=8034281 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33837518 }} </ref>. | |||
==References== | ==References== | ||
Latest revision as of 00:14, 19 March 2022
|
Bacterial pneumonia Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Bacterial pneumonia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Bacterial pneumonia cost-effectiveness of therapy |
|
Bacterial pneumonia cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Bacterial pneumonia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
The use of antibiotics and corticosteroids had proven to be a cost-effective strategy in treating community-acquired pneumonia. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective.[1] The cost effectiveness of ceftolozane/tazobactam versus meropenem was also analyzed and resulted in significant savings in early treatment.[2].
References
- ↑ Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E (2019). "The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia". Chest. 155 (4): 787–794. doi:10.1016/j.chest.2018.11.001. PMID 30448195.
- ↑ Naik J, Puzniak L, Critchlow S, Elsea D, Dillon RJ, Yang J (2021). "Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia". Infect Dis Ther. 10 (2): 939–954. doi:10.1007/s40121-021-00436-4. PMC 8034281 Check
|pmc=value (help). PMID 33837518 Check|pmid=value (help).